EFFECT OF BASELINE EPO AND PRIOR ERYTHROPOIESIS STIMULATING AGENTS ON RBC TRANSFUSION INDEPENDENCE IN LOW-/INT-1-RISK MDS WITH DEL5Q TREATED WITH LENALIDOMIDE: A RANDOMIZED PHASE 3 STUDY (MDS-004)

被引：0
|
作者：
Fenaux, P. [1 ]
Giagounidis, A. [2 ]
Selleslag, D. [3 ]
Knight, R. [4 ]
Fu, T. [4 ]
Hellstrom-Lindberg, E. [5 ]
机构：
[1] Univ Paris 13, Hop Avicenne, Bobigny, France
[2] St Johannes Hosp, Duisburg, Germany
[3] AZ St Jan Brugge AV, Brugge, Belgium
[4] Celgene Corp, Summit, NJ USA
[5] Karolinska Univ, Huddinge Hosp, Stockholm, Sweden
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0311
引用
收藏
页码：125 / 125
页数：1
相关论文
共 44 条
  • [1] RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004)
    Fenaux, Pierre
    Giagounidis, Aristotle
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mufti, Ghulam J.
    Mittelman, Moshe
    Muus, Petra
    te Boekhorst, Peter
    Sanz, Guillermo
    del Canizo, Consuelo
    Guerci-Bresler, Agnes
    Schlegelberger, Brigitte
    Aul, Carlo
    Kreipe, Hans
    Goehring, Gudrun
    Knight, Robert
    Francis, John
    Fu, Tommy
    Hellstrom-Lindberg, Eva
    BLOOD, 2009, 114 (22) : 390 - 390
  • [2] Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004)
    Fenaux, Pierre
    Giagounidis, Aristotles
    Beyne-Rauzy, Odile
    Mufti, Ghulam
    Mittelman, Moshe
    Muus, Petra
    Boekhorst, Peter Te
    Sanz, Guillermo
    Cazzola, Mario
    Backstrom, Jay
    Fu, Tommy
    Hellstrom-Lindberg, Eva
    BLOOD, 2010, 116 (21) : 1641 - 1641
  • [3] IMPACT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RBC TRANSFUSION-DEPENDENT LOW-OR INT-1-RISK MYELODYSPLASTIC SYNDROMES WITH DEL5Q: A RANDOMIZED PHASE 3 STUDY (MDS-004)
    Brandenburg, N.
    Fu, T.
    Revicki, D.
    Knight, R.
    Muus, P.
    Fenaux, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 127 - 127
  • [4] Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.
    Fenaux, P.
    Glagounidis, A.
    Selleslag, D. L.
    Beyne-Rauzy, O.
    Mittelman, M.
    Muus, P.
    Knight, R. D.
    Fu, T.
    Hellstrom-Lindberg, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis
    Fenaux, Pierre
    Giagounidis, Aristoteles
    List, Alan F.
    Nimer, Stephen D.
    Hellstrom-Lindberg, Eva
    Powell, Bayard L.
    Yu, Xujie
    Skikne, Barry
    Shammo, Jamile M.
    del Canizo, Consuelo
    BLOOD, 2011, 118 (21) : 750 - 751
  • [6] IMPACT OF 5Q BREAKPOINTS ON CLINICAL OUTCOMES IN PATIENTS WITH IPSS LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ISOLATED DEL(5Q) TREATED WITH LENALIDOMIDE IN THE MDS-004 STUDY
    Gohring, G.
    Giagounidis, A.
    List, A.
    Hellstrom-Lindberg, E.
    Sekeres, M.
    Mufti, G.
    Schlegelbergerl, B.
    Morrill, J.
    Wu, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2013, 98 : 80 - 80
  • [7] Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q
    List, A. F.
    Giagounidis, A.
    Backstrom, J. T.
    Fu, T.
    Fenaux, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004
    Giagounidis, Aristoteles
    List, Alan
    Hellstroem-Lindberg, Eva
    Sekeres, Mikkael A.
    Mufti, Ghulam J.
    Schlegelberger, Brigitte
    Morrill, John
    Wu, Chengqing
    Skikne, Barry S.
    Fenaux, Pierre
    Goehring, Gudrun
    BLOOD, 2013, 122 (21)
  • [9] Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis
    Sekeres, M.
    Swern, A.
    Fenaux, P.
    Greenberg, P.
    Sanz, G.
    Bennett, J.
    Dreyfus, F.
    Cazzola, M.
    List, A.
    Garcia-Manero, G.
    Li, J. Shiansong
    Sugrue, M.
    LEUKEMIA RESEARCH, 2013, 37 : S69 - S70
  • [10] MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q)
    Santini, V.
    Li, J. S.
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S59 - S59
12345